



## Review article

**Targeting IL-1R1-mediated neuroinflammation in central nervous system injury and disease**

Priyanshu Srivastava, Anubhav Dubey\*

Maharana Pratap College of Pharmacy, Kanpur, Uttar Pradesh, India

**Corresponding author:** Anubhav Dubey, ✉[anubhavdwivedi803@gmail.com](mailto:anubhavdwivedi803@gmail.com), **Orcid Id:** <https://orcid.org/0000-0002-9089-4794>

Maharana Pratap College of Pharmacy, Kanpur, Uttar Pradesh, India

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by-nc/4.0/>). See <https://jmpas.com/reprints-and-permissions> for full terms and conditions.**Received - 28-11-2025, Revised - 20-12-2025, Accepted - 28-01-2026 (DD-MM-YYYY)**

## Refer This Article

Priyanshu Srivastava, Anubhav Dubey, 2025. Targeting IL-1R1-mediated neuroinflammation in central nervous system injury and disease. Journal of medical pharmaceutical and allied sciences, V 15, I 1, Pages 07 – 18. Doi: <https://doi.org/10.55522/jmpas.V15I1.7004>.

**ABSTRACT**

The brain and spinal cord (CNS) was thought to be "immune privileged" for a long time, meaning that it neither caused nor was vulnerable to inflammation. In response to injury, infection, or illness, resident CNS cells produce inflammatory mediators, such as proinflammatory cytokines, prostaglandins, or free radicals, and complement. These hormones then trigger chemokines and adhesion molecules, attract immune cells, and on the other hand, inflammatory mediators may play two roles: they might be harmful in the short term but helpful in the long run. Glial cells in activation. Due to its location at the "epicentre" of inflammatory signalling networks, the interleukin one transmitter type 1 (IL-1R1) plays crucial roles in how the immune system functions. One known aspect of the autoimmune reaction in the brain and spinal cord (CNS) after injury and disease is elevated levels of cytokines, such as IL-1, or neuroinflammation. The functions of IL-1R1 in the brain cellular environment remain controversial despite the fact that IL-1/IL-1R1 signalling within the CNS has been the focus of numerous investigations. The pathophysiology of numerous CNS disease states, including Alzheimer's disease (AD), Parkinson's syndrome (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), schizophrenia, and prion diseases, is unquestionably closely associated with the ongoing stimulation of the IL-1/IL-1R1 signalling pathway. Crucially, an increasing amount of research indicates that in several animal models of the aforementioned CNS illnesses, inhibiting IL-1R1 signalling by pharmacological or genetically means results in decreased neurological inflammation and delayed progression of the disease. This paper aims to discuss recent developments in the cellular functions of IL-1R1 and to highlight important features that make IL-1R1 an attractive target for the creation of new disease-modifying therapies for various CNS diseases.

**Keywords:** Interleukin-1, Interleukin-1 receptor type 1, Neuroinflammation, CNS diseases, Tracability, Brain injury.**INTRODUCTION**

The primary defence mechanism of the host against injury, tissue ischaemia, autoimmune reactions, or infectious pathogens is inflammation. Locally, inflammation appears as the classic symptoms of swelling, redness, heat, and frequently pain in tissue outside the brain. Invasion of circulating immune cells (such as lymphocytes and macrophages) and production or production of inflammatory mediators, including kinins, cyclooxygenase products, and cytokines, are examples of more basic definitions of disease that have recently been created. Since many of these molecules develop locally and be involved in tissue inflammation, they are important targets for


therapeutic intervention in a variety of diseases. The IL-1, which was the first interleukin to be isolated, is present in this group in two different forms: IL-1 $\alpha$  & IL-1 $\beta$  [1,2]. It is a cytokine with multiple functions with a wide range of biological functions that are far from being limited to inflammation promotion, such as (i) immune cell development and maturation, (ii) fever, (iii) insulin and lipid metabolism regulation, and (iv) stress response regulation through the inhibition of the hypothalamic-pituitary-adrenal (HPA) axis [3,4]. IL-1 $\alpha$  and IL-1 $\beta$  bind through the IL-1 receptor kind 1 (IL-1R1) to mediate their biological effects. Matrix metalloproteases have the

ability to break the membrane-bound protein IL-1R1 into a readily soluble, circulating form. Via agonistic and opposing modulation of cytokine activity, both the membrane-bound and soluble versions of IL-1R1 are physiologically active and control the inflammatory response [5,6]. Crucially, elevation of IL-1 expression may lead to greater tissue damage and worsened inflammation. Numerous human pathologies, including rheumatism, diabetes type II, cancer, neurodegenerative illnesses, and monogenic autoinflammatory diseases like cryopyrin-related intermittent syndromes (CAPS) and familial Mediterranean fever (FMF), have been found to have elevated levels of the inflammatory cytokine IL-1. Therefore, since its discovery, the regulatory function of the IL-1R1 receptor in the inflammation cascades has garnered significant attention and excitement in the realm of drug discovery. Recent years have seen a resurgence of interest in the topic due to growing knowledge of the immune system's role in both the onset and progression of CNS disorders, such as Parkinson's disease (PD), dementia (AD), amyotrophic lateral sclerosis, or (ALS) and other Neurological conditions like multiple sclerosis head trauma depression and schizophrenia have all been connected to neuroinflammation. The idea that exaggeration of your immune system is a key factor in the formation of these diseases is supported by the implication of the inflammation landscape in these conditions. All of the disorders mentioned seem to be influenced by three primary causes, which are complimentary in many ways: (i) neural cell activation is an acute and constant feature to the course of the illness, whose phenotype as well as activity can fluctuate over time; (ii) a whole assortment of neuronal–glia interactions perpetuate and propagate the inflammatory response; (iii) chemicals, whether in a protective or damaging capacity (or both), function in the various disease stages, holding universal and global impacts and displaying changes in number and distinctive characteristics in all cell types. Because of its crucial function in the immune response, IL-1R1 is a valuable target in the hunt for treatments for neuroinflammation-related CNS disorders.

### CNS regulation of inflammation

It was surprising to learn that the central nervous system (CNS) controls some, if not many, aspects of immune responses and systemic inflammation. However, interleukin (IL)-1 was the first member of the cytokines, a family of proteins essential for controlling inflammation. After being identified as a significant endogenous pyrogen, IL-1 is now known as the "prototypic inflammatory cytokine." It has long been known that IL-1 is a strong endogenous and exogenous inducer of fever, which is caused by a shift in hypothalamus thermoregulation. There have been several peripheral implications of IL-1 on systemic damage since it was originally demonstrated to function in the brain. It has been determined that the brain controls numerous elements of infection and inflammation. The acute phase response and systemic inflammation. The release of flowing inflammatory chemicals like IL-6 (IL-1 is not easily detected in plasma), as well as local (like C-fibre) and more general (like vagal) neuronal signals, seems to be among the afferent messages that travel from inflamed, injured, or infected tissues to the central nervous system (CNS). Since cerebral injury could produce reactions like fever and neuroendocrine alterations within 30 minutes, it is evident that it detects peripheral injuries quickly. The CNS controls neuroendocrine and thermoregulatory reactions to illness and injury, which is not surprising; however, it additionally may have an unanticipated impact on peripheral immune function. It is now acknowledged that numerous facets of the host defensive response are coordinated and regulated by the brain, which may help to explain behavioural reactions to illness, such as despair and exhaustion, as well as how psychological status might affect susceptibility to illness and subsequent recovery. Due to its possible connection to conditions that include sudden brain injury, stroke, and other disorders, inflammation in the central nervous system has attracted a lot of attention. Alzheimer's illness, epilepsy, multiple sclerosis, a condition known as motor movement problems, and, more recently, various mental conditions like schizophrenia, depression, and anxiety [7,8].

**Figure 1:** Operations of IL-1 downstream. Inflammation and brain damage stimulate cells, such as microglia, which produce IL-1, which then acts on the type 1 IL-1 receptors to trigger a variety of downstream implications. The effects of IL-1 may be inhibited by IL-1ra




### IL-1R1 signaling

The IL-1R1 genome, which is found at band 2q12 on the extended portion of chromosomes 2, encodes human IL-1R1. IL-1R1 exists as an Eighty kDa transmembrane protein that is biologically active. It is a member of the interleukin-1 transmitter (IL-1R) family, its structural characteristic is its incorporation of intravenous (Ig)-like regions in the extracellular bound to ligand region of the receptors. Additionally, IL-1R1 has a plasmic TIR domain that initiates intracellular signalling and a transmembrane  $\alpha$ -helix [9]. Furthermore, there is a second known IL-1 receptor. The 66 kDa glycoprotein known as IL-1 receptor, type 2 (IL-1R2). This is a decoy target for IL-1 and is distinguished by the absence of an internal TIR domain [10,11]. At the peptide level, the IL-1R1 proteins from mice and humans are 69% similar. The insoluble hormones IL-1 $\alpha$  when IL-1 $\beta$  interact with the extracellular region of IL-1R1 to recruit an accessory receptor, IL-1RAcP. This results in a functional receptor complex that starts the IL-1R1 signalling cascade. The heterotrimeric IL-1/IL-1R1/IL-1RAcP complex causes the TIR domains of IL-1R1 and named IL-1RAcP proteins to dimerise, creating an anchor point for

recruiting and hiring of the inflammatory differentiation primary response protein 88. Other signalling molecules including TNF receptor- related factor 6 (TRAF6) and IL-1R-associated kinases (IRAKs) are drawn to the protein complex as a result of this protein–protein interaction. Numerous cell phosphorylation and ubiquitination mechanisms then result in the activation of nuclear factor kappa B (NF- $\kappa$ B), c-Jun N-terminal kinase (JNK), and MAPK, or mitogen-activated protein kinase p38. Inflammation-related enzymes generating IL-6, IL-8, nitric oxide synthase that is inducible (iNOS), etc.) monocyte chemoattractant protein one (MCP-1), cyclooxygenase-2 (COX-2), and I $\kappa$ B $\alpha$ , IL-1 $\alpha$ , IL-1 $\beta$ , and MAPK phosphatase 1 (MKP-1) have their mRNA transcription upregulated as a result of these alterations. In addition to the ligands IL-1 $\alpha$  and IL-1 $\beta$ , the IL-1R1 receptor also binds a physiological antagonist called IL-1Ra. Since IL-1Ra cannot cause IL-1R1 associated with IL-1RAcP, IL-1R1 binding competitively blocks IL-1 signalling. The four ligands, IL-1 $\alpha$ , IL-1 $\beta$ , and IL-1Ra, are bound by IL-1R1 with similar values (0.1 to 1 nMKd).


**Figure 2:** Showing an illustration of the IL-1 $\beta$ /IL-1R1/IL-1RAcP ternary complex [12]



Freestanding IL-1 receptor (sIL-1R) also influences the biological actions of IL-1 [13]. Detachable IL-1 receptors (sIL-1R1, sIL-1R2, and sIL-1RAcP) are released from cell membranes mostly through subsequent shedding of the outside Ig domains. The soluble external IL-1 receptor domains (also known as sIL-1R1) is capable of attachment to IL-1 monomers in solution in the extracellular surroundings, thereby blocking signal transmission. Additionally, the beneficial impacts of this antibody receptor antagonist on the inner membrane receptor are limited since sIL-1R1 binds IL-1Ra. Similar to this, sIL-1R2 functions as a lure receptor by recruiting sIL-1RAcP and binding IL-1 $\beta$  with a large affinity without initiating intracellular signalling. Unlike sIL-1R1, IL-1Ra has a modest affinity for this soluble decoy, and each IL-1Ra and sIL-1R2 work together to negatively regulate IL-1. This signalling system has an amazing

amplification power. Many intracellular molecules with basic immunoregulation mechanisms are catalyzed by the relationship of IL-1 to the transmembrane IL-1R1. At each stage of the process, the domino-like avalanche of IL-1 activation and enhancement of signal keeps getting stronger. Crucially, to control the inflammatory reaction, good modulators (receptor agonists) and adverse modulating substances (also called receptor antagonists or decoy receptors) work together. Conditions like peptides made from amyloid (A $\beta$ ) aggregates and  $\alpha$ -synuclein aggregates, LPS, lipopolysaccharide, or even injury, can cause IL-1R1 signalling dysregulation, creating a potent pro-inflammatory milieu that leads to severe consequences. Finding possible medical targets within the elements of the IL-1 aggressive pathway is necessary because IL-1 signalling has been linked to a number of inflammatory illnesses.

**Figure 3:** Schematic representation of IL-1 signaling. Upon binding of IL-1 $\alpha/\beta$  to the extracellular domain of membrane-bound receptor IL-1R1, IL-1RAcP is recruited and signaling is initiated by the interaction of the intracellular TIR domains of the two polypeptide chains <sup>[14]</sup>




### Expression of IL-1R1 in the CNS

IL-1R1, which is primarily produced by immune system cells, functions as a crucial cytokine receptor in inflammation and immunological responses throughout the body. The cortical cell layer of the brain's its dentate gyrus, the cerebellum, pituitary gland, and hypothalamus have all been connected to IL-1R1's role in the brain <sup>[15]</sup>. Within the cellular machinery of the central nervous system, vascular endothelial cells have significant expression of functional IL-1R1, whereas microglia, astrocytes, and neurones exhibit lower but discernible expression recently used chromosomal mutant reporter mice to research the cytoarchitecture and particular cell-type functions of IL-1R1 in the central nervous system They showed that monocyte recruitment is regulated by ventricular IL-1R1. in contrast to recent research that shown that astrocyte activation is driven by IL-1R1-mediated signalling Nevertheless, IL-1R1 is not totally voluntary in microglia. In fact, some in vitro investigations indicated this receptor's expression, whereas others did not corroborate it. However, several in vivo models of nerve inflammation have been shown to have elevated microglial IL-1R1 expression, indicating IL-1R1's critical participation in the cellular mechanisms of the cerebral inflammatory response Crucially, showed that this particular receptor

is essential for microglia activation and inflammation-promoting mediator production in IL-1R1 deficient animals. including IL-6, in reaction to brain damage findings suggested that an active state among human glial cells is more closely linked to IL-1R1 production throughout the central nervous system. Therefore, in pathological situations, IL-1 $\beta$  itself may stimulate IL-1R1, increasing the messenger gene levels of this receptor on glial cells. It is possible that IL-1 has a role in the natural functioning of the central nervous system after it is produced in the brain. In fact, IL-1 has been linked to the control of long-term potentiation neurogenesis sleep and fever It's interesting to note that while larger levels of IL-1 are thought to impair memory and sensory function, lower levels have been shown to aid with memory consolidation The primary source of IL-1 $\beta$  is microglia and astrocytes. When released, it can bind to IL-1R1 to further increase the production of itself in an intrinsic or porcine way manner, as well as trigger the release of other inflammatory mediators <sup>[16]</sup>. Crucially, this dynamic signaling network of IL-1 $\beta$  produced by activated glia guarantees that damage signals spread throughout the cellular milieu, causing strong neuroinflammatory alterations in the brain.



**Figure 4:** CNS cellular communication of IL-1 signaling in neuronal injury. In the normal brain, the expression of IL-1 is low, although acute CNS injury causes a sharp increase in IL-1 production<sup>[17]</sup>



#### IL-1 pathways' function and involvement in CNS disorders

Many CNS pathological conditions, including AD PD, neurological disorders such as multiple sclerosis, or MS, trauma to the head, Creutzfeldt-Jakob condition, HIV-1 encephalitis and age-related retinal degeneration, are caused by excessive IL-1R1 activation. Although the exact biochemical process by which IL-1 causes neurodegeneration is yet unknown, several hints regarding the potential mechanism or mechanisms are beginning to emerge. We discuss evidence of IL-1R1's role in CNS illness in this section<sup>[18]</sup>.

#### Alzheimer's disease and IL-1R1

AD, a progressive, brain-destroying, age-related illness that affects 60–70% among the estimated fifty billion persons with dementia worldwide, is one of the greatest widely recognised instances of a disease with neuroinflammation<sup>[19]</sup>. Plaques and tangles of neurones (collections underlying hyperphosphorylated lambda protein) in the spinal cord have been identified as the two primary hallmarks of AD pathogenesis. Signalling via IL-1 $\beta$  is said to worsen AD pathogenesis among the numerous inflammatory pathways linked to the illness. The non-LR family pyrin domain contained 3 (NLRP3) inflammasome, a key hub for producing cytokines that starts later inflammatory reactions in response to intrinsic danger signals, controls IL-1 $\beta$  at the molecular level. When stimulated, this inflammasome creates a multiprotein complex that triggers the proteolytic process of precursor proteins, resulting in the biologically active types of IL-1 $\beta$  and IL-18, which are two crucial mediators of inflammation that are markedly elevated in brains with Alzheimer's. The calcium-dependent calmodulin kinase proteins category II subunits alpha (CaMKII $\alpha$ ), which is essential for

tau excessive phosphorylation and assembly in AD, cannot be induced in dogs lacking the NLRP3 inflammasome, according to a new study by Ising and colleagues. On the other hand, tau aggregation in neurones is encouraged, and CaMKII $\alpha$  levels are raised by microglia-derived IL-1 $\beta$  through microglial NLRP3 activation. In parallel, a different recent study found a connection between the endosomal adapter target on Myb1 (TOM1) and IL-1R1 levels in AD patients' brains. The cytosolic protein TOM1 ensures the downregulation of responses to inflammation and prevents excessive IL-1R1 signalling by internalising the IL-1R1–IL-1 $\beta$  combination into endosomes<sup>[20]</sup>. According to Martini et al., there is a large decrease in TOM1 in human AD brains, which is linked to an increase in IL-1R1 levels. Following activation with diffusible ligands produced from A $\beta$ , the levels of the mentioned receptor were markedly elevated in primary hippocampus neuronal cells. Similarly, elevated levels of IL-1R1 and IL-1 $\beta$  were linked to lower levels of TOM1 in the brains of AD transgenic mice. In line with these findings, transgenic mice with AD injected with adeno- (AAV) constructs intended to either over express or knock-down TOM1 displayed higher IL-1R1 levels on neuronal cell membranes, increased A plaque accumulation, impaired microglia phagocytosis, and a shift towards a more inflammatory immune microenvironment. It's interesting to note that no notable alterations were found in other proinflammatory receptors, for instance toll-like receptors 4 (TLR4) and tumour necrosis factor the receptor (TNFR), indicating that TOM1 and IL-1R1 are closely related in the pathophysiology of AD. Conversely, collectively highlight a crucial mechanism that links IL-1 $\beta$  and IL-1R1 to A $\beta$  accumulation<sup>[21]</sup>.

### Parkinson's disease and IL-1R1

The formation of aggregate kinds of defective  $\alpha$ -synuclein (also known as Lewy aggregates) in the substance nigra (SN) region of the brain is thought to be the primary cause of Parkinson's disease (PD). These aberrant aggregates of proteins have been identified as a key cause of the imbalance in cellular homeostasis and the gradual degradation of dopaminergic neurones. The participation of several indigenous and adaptive inflammatory mechanisms within the brain and periphery of PD patients is becoming increasingly acknowledged, even though these molecular pathways underpinning the synuclein propagation in PD are still unclear [22]. PD patients' CSF (cerebrospinal fluid striatum and SN have all been shown to express more IL-1 $\beta$ . LPS or an adenovirus expressing IL-1 was injected into the SN of mice that had previously been exposed to 6-hydroxydopamine (6-OHDA), a neurotoxin used to induce Parkinson's illness (PD). This resulted in the activation of the microglia towards a favourable phenotype, increasing the secretion of IL-1 $\beta$  and a chemokine, MCP-1 and decreasing the levels of IL-4, an anti-inflammatory cytokine. Stojakovic et al. used IL-1Ra knockout mice to assess the role on the IL-1 pathway in dopamine-responsive neurone degeneration and the ability to move during ageing. Notably, IL-1Ra administration decreased LPS-induced tumour degeneration factor- $\alpha$  (TNF- $\alpha$ ) along with interferon- $\gamma$  (IFN- $\gamma$ ) expression and offset the contribution of 6-OHDA exposure to the accelerated loss of dopaminergic neurones. Overactivity of the inflammatory pathway was linked to prolonged microglia activation and increased neuroinflammation in mice deficient in IL-1Ra. According to a recent study, a greater amount of  $\alpha$ -synucleinopathy in the nose is linked to IL-1 $\beta$ /IL-1R1 signalling, which then extends to the SN and causes dopaminergic neurones to die. used animal models to confirm that LPS oral infusion increased the amounts of phosphorylated total  $\beta$ -synuclein in the gustatory bulb and SN of mice by activating microglial cells in the olfactory bulb, SN, and cerebellum in an IL-1R1-dependent way [23,24].

### IL-1R1 in multiple sclerosis

Inflammation and destruction of the central nervous system are hallmarks of multiple sclerosis (MS), a chronic autoimmune illness. The IL-1/IL-1R1 signalling network is thought to be crucial for the pathogenesis of this illness among the inflammatory signalling pathways involved [25]. Specifically, elevated levels of IL-1 $\beta$  were found in animal models of experimentally acquired encephalomyelitis (EAE), an autoimmune model specifically used to study neurones demyelination, neuroinflammation, and activity of the immune system as well as in chronic current lesions and CSF specimens of MS patients. Although IL-1R1 signalling has been connected to the activation of immune system (Th) 17 immune cells, which are crucial for the creation of autoimmune illness, the

molecular mechanism whereby IL-1 exerts harmful effects remains unclear. Granulocyte macrophage colony-stimulating factor (GM-CSF), a crucial cytokine that triggers myeloid cell activation and migration to inflammatory areas, has been shown to be upregulated in Th17 cells treated with IL-1 $\beta$ . IL-1R1 activity in lymphocytes is necessary for Th17 cell development, as evidenced by the decreased prevalence of EAE and the beginning of clinical symptoms in IL-1R1 mouse knockout models. These findings are consistent with other publications using IL-1Ra therapy or siIL-1R1 injection in EAE, which show a considerable delay in EAE clinical symptoms, a decrease in the degree of paralysis, and a decrease in the presence of CNS lesions. Evidence suggests that endothelium IL-1R1 is also a major factor in EAE. High quantities of IL-1R1 are known to be expressed by vascular endothelial cells (ECs) within the BBB cellular machinery, particularly in the pial venous plexus, a region that is the main location of haematopoietic cell migration during early EAE. Indeed, during neuroinflammation, these cells migrate across the blood-brain barrier (BBB) and secrete IL-1 $\beta$  [26], which initiates endothelial IL-1R1 signalling and subsequently induces the admission of the neutrophils as well as T cells into the central nervous system (CNS). It has been shown that disablement of IL-1R1 in mouse ECs reduces the incidence, severity, and delayed onset of the condition. Consequently, a recent investigation aiming to comprehend the cell-type-specific function of IL-1 signalling in the pathophysiology of EAE revealed that the removal of IL-1R1. According to their research, IL-1 $\beta$ /IL-1R1 signalling is essential for myeloid cell recruitment throughout the central nervous system. These results demonstrate that a protein called activation in the endothelial cells is essential for mds cell recruitment and BBB rupture, enhancing the neuroinflammatory response, albeit it is still unclear if endothelial IL-1R1 is a crucial mediator of MS pathogenesis. Targeting endothelium IL-1R1 may create therapeutic options for neuroprotection in MS, according to mounting data from both EAE and MS [27].

### Schizophrenia and IL-1R1

Multiple hereditary and environmental risk factors contribute to the complex neuropsychiatric illness known as schizophrenia, which has a varied aetiology. The impact of immunological processes leading to inflammation is becoming increasingly acknowledged, even though the mechanisms underlying the aetiology of this illness are still unknown. Numerous investigations have assessed the levels of inflammatory cytokines in schizophrenia, showing lower levels of IL-1 $\alpha$  and higher amounts of IL-1 along with IL-1Ra in their plasma. The role of IL-1R1 in schizophrenia is still mostly discovered that when schizophrenia patients' lymphocytes were compared to control subjects, mRNA

concentrations of the transcription factors IL-1R1, IL-9, TNF- $\alpha$ , TNFR1, as well as TNFR2 were significantly elevated. The function of IL-1R1 in schizophrenia is still mostly unknown. When schizophrenic patients' lymphocytes were compared to control people, discovered that the messenger RNA levels of IL-1R1, IL-6, TNF- $\alpha$ , TNFR1, and TNFR2 were significantly higher, indicating that these inflammatory players could be helpful indicators or targets for therapeutic methods [28]. Additionally, a significant elevation of IL-1 $\beta$  was found in the CSF in people with first-episode schizophrenia. The authors speculate that elevated levels of IL-1 $\beta$ , and thus IL-1 $\beta$ /IL-1R1 signaling-mediated impacts may be normalised or downregulated during the course of the disease or during extended antipsychotic treatment [29]. In contrast to numerous publications that indicate elevated levels of IL-1 $\beta$  as well as IL-1Ra in psychosis, other research revealed lower or no discernible changes in these cytokines' levels. Because of this, the findings and observations pertaining to IL-1 cytokines & their associated receptors are still highly ambiguous and should be evaluated cautiously [30].

#### **Epilepsy and IL-1R1**

It is assumed that IL-1 signalling plays a role in the pathogenesis of epilepsy because multiple lines of evidence have demonstrated that IL-1 $\beta$  increases seizures in experimental forms of epilepsy [31]. A distorted neuroinflammatory response is thought to play an infectious component in this neurological illness, which is characterised by a persistent propensity of the cerebellum to develop epileptic seizures. IL-1R1 expression profiles, while epileptic episodes were found to be starting upregulated in hippocampal neurones, after which there was a delay in and a brief surge in cell types in the cerebellum and exterior brain areas. This suggests that IL-1 $\beta$  can further boost IL-1R1 production through autocrine or paracrine signalling. Due to its possible involvement in the onset and aggravation of seizures, the IL-1R1/TLR4 signalling pathway has been extensively researched. In murine models, it was demonstrated that their endogenous ligands, IL-1 $\beta$  and HMGB1, respectively, were elevated after acute seizure activity [32]. Crucially, Iori et al. discovered that blocking the IL-1R1/TLR4 axis using an experimental TLR4 antagonist and the caspase-1 inhibitor VX-765 successfully slowed the progression of the disease and dramatically decreased periodic seizures by 90% Growing evidence that blocking IL-1R1 through pharmacological or genetic techniques significantly reduces seizure susceptibility lends more credence to these observations Children from febrile-infection-related epilepsy sickness (FIRES) have recently received anakinra, which has successfully decreased the frequency of seizures [33].

#### **IL-1R1 in stroke and traumatic brain injuries**

Numerous research has examined the function of IL-1 $\beta$  in neurotoxicity after ischemic brain damage. The primary source of IL-

1 $\beta$  is thought to be microglia, and the rise in cytokine levels starts early (between 0 and 3 hours after ischaemia) and continues later because atrocities, neurons, endothelial cells, and different immune cells also express it later On the one hand, IL-1 $\beta$  has been demonstrated to significantly worsen injury and increase cell damage in human forms of cerebral ischemia However, a number of preclinical investigations found that administering IL-1Ra to suppress IL-1 signaling had neuroprotective effects in ischemic stroke, including reduced tissue loss and mitigated cognitive abnormalities. Similarly, in animal brain injury (TBI) models, IL-1Ra exposure or anakinra therapy has been shown to attenuate neuronal damage [34]. The significance of this protein receptor in activation of microglia cells was highlighted by additional studies conducted by Basu and classmates employing the IL-1R1 knockout mice, which showed that the lack of IL-1 signaling following brain injury has a close association with significant reductions in cell proliferation and a form of along with IL-6 and COX-2 generated [35]. When administered to patients in the initial hours following a stroke, these and related findings led to clinical trials combining IL-1Ra and anakinra as therapies for ischemic and hemorrhagic stroke, which significantly reduced inflammation levels and improved cognitive abilities [36].

#### **IL-1R1 in additional CNS conditions**

Although the precise processes by which IL-1R1 functions in the brain are yet unknown, it is evident that this protein's role goes beyond the CNS disorders mentioned in the aforementioned subsections. For example, it was discovered that in excitotoxin-damaged mice retinas, IL-1 $\beta$  released by microglia and interacting with IL-1R1 expressed via astrocytes gives neuroprotection [37,38]. The scientists found that IL-1 $\beta$  therapy of retinas enhanced neuronal survival after an excitotoxic insult by stimulating microglia activation and proliferation. It's interesting to note that this neuroprotection was greatly diminished in IL-1R1-deficient mice, but it was restored when IL-1R1 expression was specifically restored in astrocytes. This suggests that astrocytic IL-1R1 is necessary for the effective activation of microglia and the induction of inflammatory responses in response to damage. However, some have suggested that the IL-1 $\beta$ /IL-1R1 signalling complex plays a more cytotoxic role in retinal degeneration. enhanced levels of inflammatory cytokines, such as IL-1 $\beta$ , and photoreceptor death of cells were linked to enhanced infiltration or activity of monocytes, macrophages, and microglia in a mouse model of light-induced retinopathy. Anakinra and rytvela treatment markedly reduced: (i) monocyte, macrophage, and microglia infiltration and preserved cell shape in a stretched steady-state; (ii) pro-inflammatory molecules such as of IL-1, IL-6, and CCL2; and (iii) photoreceptor apoptosis [39].

### Tractability of IL-1R1 as a pharmacological target

As previously mentioned, there is growing evidence that IL-1R1 signalling dysregulation has a causative role in a number of CNS disorders. Nevertheless, characterisation in terms of simplicity and effectiveness is crucial to increasing the chances of success in regulating IL-1R1 signalling and advancing drug discovery efforts. The creation and optimisation of targeted medicines should be encouraged and guided by the ongoing developments in the domains of virtual screening, fragment-based lead finding, structural bioinformatics, and phenotypic screening [40,41].


### Availability of protein structure

In addition to analysing general methods of signal activation and understanding suppression of the IL-1 cytokines, an understanding of the structural complexities of IL-1R1 is essential for rationalising and predicting potential binding areas for modulators [42,43]. A cytoplasmic domain (TM) and an intermediate 217 nitrogen-containing TIR domain support the question-mark-shaped structure of IL-1R1, a transmembrane signaling receptor with a 319 amino acid ectodomain. Set the foundation for the IL-1R1 ectodomain's structural elucidation (henceforth referred to as IL-1R1-ECD). It describes the region's 3D crystal structure characterised at 2.5 Å resolution. The three Ig-like domains that the IL-1R1-ECD folds into are called D1, D2, and D3. A large  $\beta$ -structure made up of seven to nine strands characterises each domain disappplied linkages comprising pairings of exceptionally stable cysteine amino acids in the IL-1 receptor family, which are organised into a two-layered sandwich. A disordered bond connects the two like Ig domains that form D1 and D2, whereas a flexible, six-amino acid linker without a secondary structure keeps D3 apart. The Protein Data Bank (PDB) contained five crystal domes of protein complexes that contained the extracellular section of IL-1R1 [44].

### Putative IL-1R1 druggable binding sites


The initial indications of possible therapeutic binding regions on the surface of IL-1R1-ECD, using Schrödinger SiteMap the D1-D2 interface region, the adaptable linker between the similar to Ig domains D2 and D3, and the interface sector involving D1 and D3 when IL-1R1-ECD takes on a closed conformation are the three sites on the receptor surface that were expected to bind small molecules. Here, we report a place of attachment druggability analysis utilising the DoG Site Scorer system to supplement Yang's binding site analysis. DoG Site Scorer is a grid-based technique that uses support vector machines (SVM) to learn from three-dimensional protein structures and identify binding pockets and sub-pockets that have a high probability of drawing in and accommodating ligands that resemble drug [46,47]. The result for each wallet and the corresponding sub-pockets is a straightforward drug-ability score, with values ranging from 0 to 1. The possibility that the pocket is druggable increases with the score. The crystalline unstructured configuration of IL-1R1-ECD at an excellent magnification of 2.15 Å (PDB index 4GAF) was used for our binding site investigations. The ability to drug scores and computed descriptors for the main cavities found at the IL-1R1-4-ECD surface are. Ten putative binding pockets (PO) with effectiveness scores ranging from 1.18 by 0.84 were found in the IL-1R1-ECD detached conformation, according to the research. Three pockets, PO\_0, PO\_1, and PO\_2, have a significant pocket volume and druggability scores more than 0.70. a high depth and an appropriate hydrophobicity ratio, indicating that these regions have a high probability of binding small molecules. Specifically, residues essential for ligand binding overlap with the two anticipated pockets PO\_0 and PO [48,49].

**Figure 5:** Molecular structure the IL-1R1 ectodomain. The coordinates were retrieved from the PDB (PDB entry 4GAF). The Ig-like domains are labeled as D1 (orange), D2 (green) and D3 (blue), and the 6 amino acid flexible linker located between D2 and D3 is represented in yellow [45].






**Figure 6:** Alignment of IL-1R1, IL-1R2, IL-18R $\alpha$ , ST2 and IL-36R ectodomains. The  $\beta$ -strands were assigned using the DSSP algorithm and are shown for the IL-1R1 sequence (a1-g1 located in D1, a2-g2 located in D2 and a3-g3 located in D3, represented as blue arrows) <sup>[45]</sup>



**Figure 7:** Binding pocket prediction on the IL-1R1 ectodomain surface (PDB entry 4GAF), using the DoG Site Scorer tool <sup>[50]</sup>



## CONCLUSION

Important roles in the regulation of inflammation against immunological threats are played by IL-1, IL-1R1, and its downstream mediators. However, it has also been demonstrated that IL-1 has a role in a variety of human diseases that are highly prevalent and have a significant socioeconomic impact. One crucial question is brought up by this double-edged sword behavior: Is IL-1 a protective response, a pathogenic factor, or something else entirely? We think it could be all of the aforementioned, depending on the cell subtypes, signalling sub-pathways, and disease progression stage. Pharmaceutical companies appear to be less interested in IL-1R1 drug discovery despite favorable in vitro and in vivo outcomes in instances of CNS diseases. This is due to the difficulty of translating results from animal research to humans through practical clinical trials, as well as some contradictory data obtained by human studies. However, the research discussed here provides compelling evidence that IL-1R1 plays a significant role in CNS disorders. Under these circumstances, IL-1R1 is strongly set by IL-1 secreted by surrounding glial cells, and the inflammatory signal that results may cause damage to CNS tissue. This has increased the motivation to investigate IL-1R1 as a therapeutic target due to the growing number of non-clinical and IL-1R1-antagonizing biological therapies that show encouraging correlations with significant reductions in disease-linked microgliosis and astrogliosis. As the research advances, fine-tuning IL-1R1 activity might need defining a new paradigm that combines small compounds with additional therapeutic strategies like antibodies or IL-1 inhibition, like RNA interference. The creation of suitable in vitro and in animals' disease models is crucial in this endeavor to ascertain the results of modifying the IL-1 signaling pathway in the central nervous system.

## ACKNOWLEDGEMENT

We would like to thank our management for providing all the facilities for the conduct of this Study.

## REFERENCES

1. Fantuzzi G, 2016. Evolution of message discovery: The Interleukin-1 family. In *Body Messages*; Harvard University Press: Cambridge, USA. Pages 29–73.
2. Dinarello CA, 2018. Overview of the IL-1 family in innate inflammation and acquired immunity. *Immunol Rev.* 281, Pages 8–27. Doi: 10.1111/imr.12621.
3. Sims JE, Smith DE, The IL-1 family: Regulators of immunity. *Nat. Rev. Immunol.* 2010, 10, Pages 89–102. Doi: 10.1038/nri2691.
4. Mantovani A, Dinarello C A, Molgora M, 2019. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. *Immunity.* 50, Pages 778–795. Doi: 10.1016/j.immuni.2019.03.012.
5. Elzinga BM, Twomey C, Powell JC, 2009. Interleukin-1 receptor type 1 is a substrate for  $\gamma$ -secretase- dependent regulated intramembrane proteolysis. *J BiolChem.* 284, Pages 1394–1409. Doi: 10.1074/jbc.M803108200.
6. Fields JK, GüntherS, Sundberg EJ, 2019. Structural basis of IL-1 family cytokine signaling. *Front Immunol.* 10, Doi: 10.3389/fimmu.2019.01412.
7. Dinarello CA, 1984. Interleukin-1 and the pathogenesis of the acute-phase response. *N Engl J Med.* 311(22), Pages 1413–1418. Doi:10.1056/NEJM198411293112205.
8. Troncoso-Escudero P, Parra A, Nassif M, 2018. Outside in: Unraveling the role of neuroinflammation in the progression of Parkinson's disease. *Front Neurol.* 9, Doi: 10.3389/fneur.2018.00860.
9. Peters VA, Joesting JJ, Freund G, 2013. IL-1 receptor 2 (IL-1R2) and its role in immune regulation. *Brain Behav Immun.* 32, Pages 1–8. Doi: 10.1016/j.bbi.2012.11.006.
10. Schlüter T, Schelmbauer C, Karram K, 2018. Regulation of IL-1 signaling by the decoy receptor IL-1R2. *J MolMed.* 96, Pages 983–992. Doi: 10.1007/s00109-018-1684-z.
11. Dale M, Nicklin MJH, 1999. Interleukin-1 receptor cluster: Gene organization of IL1R2, IL1R1, IL1RL2(IL-1Rrp2), IL1RL1(T1/ST2), and IL18R1(IL-1Rrp) on human chromosome 2q. *Genomics.* 57, Pages 177–179. Doi: <https://doi.org/10.1006/geno.1999.5767>.
12. HumphreyW, Dalke A, Schulten K, 1996. VMD: Visual molecular dynamics. *JMol Graph.* 14, Pages 33–38. Doi: [https://doi.org/10.1016/0263-7855\(96\)00018-5](https://doi.org/10.1016/0263-7855(96)00018-5).
13. Smith DE, Hanna R, FriendD, 2003. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. *Immunity.* 18, Pages 87–96. Doi: 10.1016/s1074-7613(02)00514-9.
14. Martin P, Goldstein JD, Mermoud L, et al, 2021. IL-1 family antagonists in mouse and human skin inflammation. *Front. Immunol.* 2021, Page 652846. Doi: 10.3389/fimmu.2021.652846.
15. Cunningham E, Wada E, Carter D, et al, 1992. In situ histochemical localization of type I interleukin-1 receptor messenger RNA in the central nervous system, pituitary, and adrenal gland of the mouse. *J Neurosci.* 12, Pages 1101–1114. Doi: 10.1523/JNEUROSCI.12-03-01101.1992.
16. French RA, VanHoy RW, Chizzonite R, et al, 1999. Expression and localization of p80 and p68 interleukin-1 receptor proteins in the brain of adult mice. *J. Neuroimmunol.* 93, Pages 194–202. Doi: 10.1016/s0165-5728(98)00224-0.
17. Galundia S, Parekh H S, 2022. The role of interleukin-1 in neuroinflammation and Alzheimer's disease: An evolving perspective. *Journal of Neuroinflammation.* 19(1), Doi: 10.1186/1742-2094-5-7.
18. Zhao M L, Kim M O, Morgello S, 2001. Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis. *J. Neuroimmunol.* 115, Pages 182–191. Doi: 10.1016/s0165-5728(00)00463-x.

19. Ising C, Venegas C, Zhang S, et al, 2019. NLRP3 inflammasome activation drives tau pathology. *Nature*. 575, Pages 669–673. Doi: 10.1038/s41586-019-1769-z.
20. Bhaskar K, Konerth M, Kokiko-Cochran, et al, 2010. Regulation of Tau pathology by the microglial fractalkine receptor. *Neuron*. 68, Pages 19–31. Doi: 10.1016/j.neuron.2010.08.023.
21. Mancuso R, Fryatt G, Cleal M, et al. 2019. CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. *Brain*. Pages 142, 3243–3264. Doi: 10.1093/brain/awz241.
22. Koprach JB, Reske-Nielsen C, Mithal P, 2008. Neuroinflammation mediated by IL-1 $\beta$  increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. *J Neuroinflamm*. 5, Doi: 10.1186/1742-2094-5-8.
23. Pott Godoy, Tarelli R, Ferrari C, et al, 2008. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. *Brain*. 131, Pages 1880–1894. Doi: 10.1093/brain/awn101.
24. Pott Godoy, Ferrari C, Pitossi J, 2010. Nigral neurodegeneration triggered by striatal AdIL-1 administration can be exacerbated by systemic IL-1 expression. *J. Neuroimmunol*. Pages 29–39. Doi: 10.1016/j.jneuroim.2010.02.018.
25. Mc Guinness M, Powers J, Bias W, et al, 1997. Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinating lesions of X-linked adrenoleukodystrophy and multiple sclerosis. *J Neuroimmunol*. 75, Pages 174–182. Doi: 10.1016/s0165-5728(97)00020-9.
26. Hauser SL, Doolittle TH, Lincoln R, et al, 1990. Cytokine accumulations in CSF of multiple sclerosis patients. *Neurology*. Doi: <https://doi.org/10.1212/wnl.40.11.1735>.
27. Seppi D, Puthenparampil M, Federle L, et al, 2014. Cerebrospinal fluid IL-1 $\beta$  correlates with cortical pathology load in multiple sclerosis at clinical onset. *J. Neuroimmunol*. 270, Pages 56–60. Doi: 10.1016/j.jneuroim.2014.02.014.
28. Lesh TA, Careaga M, Rose DR, et al, 2018. Cytokine alterations in first-episode schizophrenia and bipolar disorder: Relationships to brain structure and symptoms. *J Neuroinflamm*. 15, Doi: 10.1186/s12974-018-1197-2.
29. Al-Asmari, 2014. Inflammation and schizophrenia: Alterations in cytokine levels and perturbation in antioxidative defense systems. *Hum. Exp Toxicol*. Pages 115–122. Doi: 10.1177/0960327113493305.
30. Katila H, Appelberg B, Hurme M, 1994. Plasma levels of interleukin-1 $\beta$  and interleukin-6 in schizophrenia, other psychoses, and affective disorders. *Schizophr Res*. 12, Pages 29–34. Doi: 10.1016/0920-9964(94)90081-7.
31. Ravizza T, Vezzani A, 2006. Status epilepticus induces time-dependent neuronal and astrocytic expression of interleukin-1 receptor type I in the rat limbic system. *Neuroscience*. 137, Pages 301–308. Doi: 10.1016/j.neuroscience.2005.07.063.
32. Ravizza T, Gagliardi B, Noé F, et al, 2008. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: Evidence from experimental models and human temporal lobe epilepsy. *Neurobiol. Dis*. 29, Pages 142–160. Doi: 10.1016/j.nbd.2007.08.012.
33. Maroso M, Balosso S, Ravizza T, et al, 2010. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. *Nat. Med*. 2010, 16, 413–419. Doi: 10.1038/nm.2127.
34. Alea J, Ogungbenro K, Hulme S, et al. 2018. Reduction of inflammation after administration of interleukin-1 receptor antagonist following aneurysmal subarachnoid hemorrhage: Results of the Subcutaneous Interleukin-1Ra in SAH (SCIL-SAH) study. *J. Neurosurg*. 128, Pages 515–523. Doi: 10.3171/2016.9.JNS16615.
35. Smith CJ, Hulme S, Vail A, et al, 2018. SCIL-STROKE (Subcutaneous Interleukin-1 receptor antagonist in ischemic stroke). *Stroke*. 49, Pages 1210–1216. Doi: 10.1161/STROKEAHA.118.020750.
36. Emsley HC, Smith CJ, Georgiou RF, et al, 2005. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. *J. Neurol. Neurosurg. Psychiatry*. 76, Pages 1366–1372. Doi: 10.1136/jnnp.2004.054882.
37. Wooff Y, Man SM, Aggio-Bruce R, et al, 2019. IL-1 Family members mediate cell death, inflammation and angiogenesis in retinal degenerative diseases. *Front. Immunol*. 2019, 10, Pages 1618. Doi: 10.3389/fimmu.2019.01618.
38. Dabouz R, Cheng C, Abram P, et al, 2020. An allosteric interleukin-1 receptor modulator mitigates inflammation and photoreceptor toxicity in a model of retinal degeneration. *J Neuroinflamm*. 17, Doi: 10.1186/s12974-020-02032-8.
39. Tomasoni R, Morini R, Lopez-Atalaya P, et al, 2017. Lack of IL-1R8 in neurons causes hyperactivation of IL-1 receptor pathway and induces MECP2-dependent synaptic defects. *ELife*. 6, Page e21735. Doi: 10.7554/eLife.21735.
40. Vigers A, Anderson J, Caffes P, 1997. Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1 $\beta$ . *Nature* 1997. Pages 190–194. Doi: 10.1038/386190a0.
41. Schreuder H, Tardif C, Trump-Kallmeyer, 1997. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. *Nature*. 386, Pages 194–200. Doi: 10.1038/386194a0.
42. Hou J, Townson A, Kovalchin T, et al, 2013. Design of a superior cytokine antagonist for topical ophthalmic use. *Proc. Natl. Acad. Sci*. 110, Pages 3913–3918. Doi: 10.1073/pnas.1217996110.
43. Vigers A, Dripps J, Edwards K, et al, 2000. X-ray crystal structure of a small antagonist peptide bound to interleukin-1 receptor type I. *J Biol Chem*. 275, Pages 36927–36933. Doi: 10.1074/jbc.M006071200.

44. Berman HM, Westbrook J, Feng Z, 2000. The protein data bank. *Nucleic Acids Res.* 28, Pages 235–242. Doi: 10.1093/nar/28.1.235.
45. Kabsch W, Sander C, 1983. Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features. *Biopolymers.* 22, Pages 2577–2637. Doi: 10.1002/bip.360221211.
46. Gehrke L, Jobling SA, Paik LS, 1990. A point mutation uncouples human interleukin-1 beta biological activity and receptor binding. *JBiol Chem.* 265, Pages 5922–5925.
47. MacDonald, Wingfield P, Schmeissner U, 1986. Point mutations of human interleukin-1 with decreased receptor binding affinity. *FEBS Lett.* 209, Pages 295–298.
48. Evans RJ, Bray J, ChildsJD, et al, 1995. Mapping receptor binding sites in Interleukin (IL)-1 receptor antagonist and IL-1 $\beta$  by site-directed mutagenesis. *J Biol Chem.* 270, Pages 11477–11483.
49. Ge J Remesh, SG Hammel, M Pan, et al, 2019. Functional relevance of Interleukin-1 receptor inter-domain flexibility for cytokine binding and signaling. *Structure* 2019, 27, Pages 1296–1307. Doi: 10.1016/j.str.2019.05.011.
50. Ajmone-Cat M A, Minghetti L, Visentin S, 2019. Interleukin-1 System in Central Nervous System Health and Disease: A General Overview. *International Journal of Molecular Sciences.* 20(20), Pages 5022. Doi: 10.1196/annals.1391.022.